Remove Cannabinoids Remove Clinical Trials Remove DEA
article thumbnail

‘The Doors are Wide Open’: Denver Cannabis Company Gets DEA Approval To Expand Alzheimer’s Research

Cannabis Law Report

We’re interested in how cannabinoids affect the nervous system, the brain, and in in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. According to Towle, MedPharm’s researchers hope to find whether cannabinoids can treat symptoms or even prevent the disease.

DEA 105
article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access.

Therapy 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 51
article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

research scene is also dominated by research on the harmful effects of cannabis, but Canada has dedicated much more funding to positive cannabinoid research. Non-profit organizations like the Canadian Consortium for Investigation of Cannabinoids (CCIC) were also formed to do research. The DEA would then be the exclusive distributor.

DEA 105
article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

CBD: Everything You Need to Know

CannaMD

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.

CBD 105
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Drug Enforcement Agency (DEA). We could potentially develop north of 11,000 drugs that are cannabinoid-based. According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Is the future exciting? Absolutely.”